RIBOLIFE-B Spends HK$3.83 Million to Repurchase 79,000 H Shares, Treasury Stock Climbs to 0.49 Million

Bulletin Express07-17

Suzhou Ribo Life Science Co., Ltd. (RIBOLIFE-B; HKEX: 06938) disclosed a share buyback executed on 17 July 2026. The company repurchased 79,000 H shares on the Hong Kong Stock Exchange at prices ranging from HK$45.88 to HK$50.55 per share, for a total consideration of HK$3.83 million. The volume-weighted average repurchase price was approximately HK$48.52 per share.

Following the transaction, shares held as treasury stock increased from 0.41 million to 0.49 million, while the number of issued shares excluding treasury stock fell by 0.0464% to 170.06 million. The total issued share count remains unchanged at 170.55 million.

The purchase forms part of the repurchase mandate approved on 5 June 2026, which authorises the company to buy back up to 17.06 million shares. Cumulative buybacks under this mandate now total 0.49 million shares, representing 0.29% of the issued share base as at the mandate date.

In accordance with Hong Kong Stock Exchange rules, RIBOLIFE-B is subject to a moratorium on issuing new shares or disposing of treasury shares until 16 August 2026.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1152367346?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-17 19:21","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1152367346","market":"us","top_or_hot":-1,"title":"RIBOLIFE-B Spends HK$3.83 Million to Repurchase 79,000 H Shares, Treasury Stock Climbs to 0.49 Million","media":"Bulletin Express","content":"<p>Suzhou Ribo Life Science Co., Ltd. (RIBOLIFE-B; HKEX: 06938) disclosed a share buyback executed on 17 July 2026. The company repurchased 79,000 H shares on the Hong Kong Stock Exchange at prices ranging from HK$45.88 to HK$50.55 per share, for a total consideration of HK$3.83 million. The volume-weighted average repurchase price was approximately HK$48.52 per share.</p>\n<p>Following the transaction, shares held as treasury stock increased from 0.41 million to 0.49 million, while the number of issued shares excluding treasury stock fell by 0.0464% to 170.06 million. The total issued share count remains unchanged at 170.55 million.</p>\n<p>The purchase forms part of the repurchase mandate approved on 5 June 2026, which authorises the company to buy back up to 17.06 million shares. Cumulative buybacks under this mandate now total 0.49 million shares, representing 0.29% of the issued share base as at the mandate date.</p>\n<p>In accordance with Hong Kong Stock Exchange rules, RIBOLIFE-B is subject to a moratorium on issuing new shares or disposing of treasury shares until 16 August 2026.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>RIBOLIFE-B Spends HK$3.83 Million to Repurchase 79,000 H Shares, Treasury Stock Climbs to 0.49 Million</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRIBOLIFE-B Spends HK$3.83 Million to Repurchase 79,000 H Shares, Treasury Stock Climbs to 0.49 Million\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-07-17 19:21</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Suzhou Ribo Life Science Co., Ltd. (RIBOLIFE-B; HKEX: 06938) disclosed a share buyback executed on 17 July 2026. The company repurchased 79,000 H shares on the Hong Kong Stock Exchange at prices ranging from HK$45.88 to HK$50.55 per share, for a total consideration of HK$3.83 million. The volume-weighted average repurchase price was approximately HK$48.52 per share.</p>\n<p>Following the transaction, shares held as treasury stock increased from 0.41 million to 0.49 million, while the number of issued shares excluding treasury stock fell by 0.0464% to 170.06 million. The total issued share count remains unchanged at 170.55 million.</p>\n<p>The purchase forms part of the repurchase mandate approved on 5 June 2026, which authorises the company to buy back up to 17.06 million shares. Cumulative buybacks under this mandate now total 0.49 million shares, representing 0.29% of the issued share base as at the mandate date.</p>\n<p>In accordance with Hong Kong Stock Exchange rules, RIBOLIFE-B is subject to a moratorium on issuing new shares or disposing of treasury shares until 16 August 2026.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"06938","symbol_name":"瑞博生物-B","start_time":0,"source_url":"","article_id":"1152367346","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1152367346","pubTimestamp":1784287280,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Suzhou Ribo Life Science Co., Ltd. (RIBOLIFE-B; HKEX: 06938) disclosed a share buyback executed on 17 July 2026. The company repurchased 79,000 H shares on the Hong Kong Stock Exchange at prices...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"06938":"瑞博生物-B"},"translate_title":"RIBOLIFE-B斥资383万港元回购7.9万股H股，库存股攀升至49万股","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"06938":1},"content_text":"Suzhou Ribo Life Science Co., Ltd. (RIBOLIFE-B; HKEX: 06938) disclosed a share buyback executed on 17 July 2026. The company repurchased 79,000 H shares on the Hong Kong Stock Exchange at prices ranging from HK$45.88 to HK$50.55 per share, for a total consideration of HK$3.83 million. The volume-weighted average repurchase price was approximately HK$48.52 per share.\nFollowing the transaction, shares held as treasury stock increased from 0.41 million to 0.49 million, while the number of issued shares excluding treasury stock fell by 0.0464% to 170.06 million. The total issued share count remains unchanged at 170.55 million.\nThe purchase forms part of the repurchase mandate approved on 5 June 2026, which authorises the company to buy back up to 17.06 million shares. Cumulative buybacks under this mandate now total 0.49 million shares, representing 0.29% of the issued share base as at the mandate date.\nIn accordance with Hong Kong Stock Exchange rules, RIBOLIFE-B is subject to a moratorium on issuing new shares or disposing of treasury shares until 16 August 2026.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"shareholding,SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.46.0","shortVersion":"4.46.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1152367346","isCrawlerRequest":true}